Oral microbiota as a biomarker for predicting the risk of malignancy in indeterminate pulmonary nodules: a prospective multicenter study
- PMID: 39728732
- DOI: 10.1097/JS9.0000000000002152
Oral microbiota as a biomarker for predicting the risk of malignancy in indeterminate pulmonary nodules: a prospective multicenter study
Abstract
Background: Determining the benign or malignant status of indeterminate pulmonary nodules (IPN) with intermediate malignancy risk is a significant clinical challenge. Oral microbiota-lung cancer (LC) interactions have qualified oral microbiota as a promising non-invasive predictive biomarker in IPN.
Materials and methods: Prospectively collected saliva, throat swabs, and tongue coating samples from 1040 IPN patients and 70 healthy controls across three hospitals. Following up, the IPNs were diagnosed as benign (BPN) or malignant pulmonary nodules (MPN). Through 16S rRNA sequencing, bioinformatics analysis, fluorescence in situ hybridization (FISH), and seven machine learning algorithms (support vector machine, logistic regression, naïve Bayes, multi-layer perceptron, random forest, gradient-boosting decision tree, and LightGBM), we revealed the oral microbiota characteristics at different stages of HC-BPN-MPN, identified the sample types with the highest predictive potential, constructed and evaluated the optimal MPN prediction model for predictive efficacy, and determined microbial biomarkers. Additionally, based on the SHAP algorithm interpretation of the ML model's output, we have developed a visualized IPN risk prediction system on the web.
Results: Saliva, tongue coating, and throat swab microbiotas exhibit site-specific characteristics, with saliva microbiota being the optimal sample type for disease prediction. The saliva-LightGBM model demonstrated the best predictive performance (AUC = 0.887, 95%CI: 0.865-0.918), and identified Actinomyces, Rothia, Streptococcus, Prevotella, Porphyromonas , and Veillonella as biomarkers for predicting MPN. FISH was used to confirm the presence of a microbiota within tumors, and external data from a LC cohort, along with three non-IPN disease cohorts, were employed to validate the specificity of the microbial biomarkers. Notably, coabundance analysis of the ecological network revealed that microbial biomarkers exhibit richer interspecies connections within the MPN, which may contribute to the pathogenesis of MPN.
Conclusion: This study presents a new predictive strategy for the clinic to determine MPNs from BPNs, which aids in the surgical decision-making for IPN.
Copyright © 2025 The Author(s). Published by Wolters Kluwer Health, Inc.
Similar articles
-
Diagnostic potential of salivary microbiota in persistent pulmonary nodules: identifying biomarkers and functional pathways using 16S rRNA sequencing and machine learning.J Transl Med. 2024 Nov 28;22(1):1079. doi: 10.1186/s12967-024-05802-7. J Transl Med. 2024. PMID: 39609902 Free PMC article.
-
16S rRNA sequencing reveals relationships among enrichment of oral microbiota in the lower respiratory tract and pulmonary nodules malignant progression.Microbiol Spectr. 2025 Mar 4;13(3):e0128424. doi: 10.1128/spectrum.01284-24. Epub 2025 Feb 5. Microbiol Spectr. 2025. PMID: 39907436 Free PMC article.
-
Exploring non-invasive biomarkers for pulmonary nodule detection based on salivary microbiomics and machine learning algorithms.Sci Rep. 2025 Mar 29;15(1):10848. doi: 10.1038/s41598-025-95692-6. Sci Rep. 2025. PMID: 40155734 Free PMC article.
-
A prediction model based on DNA methylation biomarkers and radiological characteristics for identifying malignant from benign pulmonary nodules.BMC Cancer. 2021 Mar 10;21(1):263. doi: 10.1186/s12885-021-08002-4. BMC Cancer. 2021. PMID: 33691657 Free PMC article.
-
Saliva‑microbiome‑derived signatures: expected to become a potential biomarker for pulmonary nodules (MCEPN-1).BMC Microbiol. 2024 Apr 20;24(1):132. doi: 10.1186/s12866-024-03280-x. BMC Microbiol. 2024. PMID: 38643115 Free PMC article.
Cited by
-
Worldwide Research Trends on Lung Cancer and Microbiota: A Bibliometric and Visualized Analysis.J Multidiscip Healthc. 2025 Jul 29;18:4291-4308. doi: 10.2147/JMDH.S516036. eCollection 2025. J Multidiscip Healthc. 2025. PMID: 40761583 Free PMC article. Review.
References
-
- Yang CY, Lin YT, Lin LJ, et al. Stage shift improves lung cancer survival: real-world evidence. J Thorac Oncol 2023;18:47–56.
-
- Leiter A, Veluswamy RR, Wisnivesky JP. The global burden of lung cancer: current status and future trends. Nat Rev Clin Oncol 2023;20:624–39.
-
- Bonney A, Malouf R, Marchal C, et al. Impact of low-dose computed tomography (LDCT) screening on lung cancer-related mortality. Cochrane Database Syst Rev 2022;8:CD013829.
-
- Mazzone PJ, Lam L. Evaluating the Patient With a Pulmonary Nodule: a Review. Jama 2022;327:264–73.
-
- Nair VS, Sundaram V, Desai M, Gould MK. Accuracy of models to identify lung nodule cancer risk in the National Lung Screening Trial. Am J Respir Crit Care Med 2018;197:1220–23.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical